首页> 外国专利> Controlled release formulation of opioid and non-opioid analgesics

Controlled release formulation of opioid and non-opioid analgesics

机译:阿片类和非阿片类镇痛药的控释制剂

摘要

Sustained release dosage forms for twice daily oral dosing to a human patient for providing relief from pain are provided. The sustained release dosage form comprises an immediate release component and a sustained release component, wherein the immediate release component and the sustained release component collectively contain a therapeutically effective amount of an opioid analgesic and a therapeutically effective amount of nonopioid analgesic. In a preferred embodiment, the nonopioid analgesic is acetaminophen and the opioid analgesic is hydrocodone and pharmaceutically acceptable salts thereof, and in preferred embodiments, the pharmaceutically acceptable salt is bitartrate. The dosage forms produce plasma profiles in a patient characterized by a Cmax for hydrocodone of between about 0.6 ng/mL/mg to about 1.4 ng/mL/mg and an AUC for hydrocodone of between about 9.1 ng*hr/mL/mg to about 19.9 ng*hr/mL/mg (per mg hydrocodone bitartrate administered) and a Cmax for acetaminophen of between about 2.8 ng/mL/mg and 7.9 ng/mL/mg and an AUC for acetaminophen of between about 28.6 ng*hr/mL/mg and about 59.1 ng*hr/mL/mg (per mg acetaminophen administered) after a single dose.
机译:提供了用于向人类患者每天两次口服给药以减轻疼痛的缓释剂型。缓释剂型包含速释组分和缓释组分,其中速释组分和缓释组分共同包含治疗有效量的阿片类镇痛药和治疗有效量的非阿片类镇痛药。在一个优选的实施方案中,非阿片类镇痛药是对乙酰氨基酚,而阿片类镇痛剂是氢可酮及其药学上可接受的盐,并且在优选的实施方案中,药学上可接受的盐是酒石酸氢盐。剂型在患者中产生血浆特征,其特征在于氢可酮的C max为约0.6ng / mL / mg至约1.4ng / mL / mg,而氢可酮的AUC为约9.1ng / hr / mL / mg至约0.1ng / hr / mL。 19.9 ng * hr / mL / mg(每毫克酒石酸氢可酮),对乙酰氨基酚的Cmax在约2.8 ng / mL / mg和7.9 ng / mL / mg之间,对乙酰氨基酚的AUC在约28.6 ng * hr / mL之间单剂量后,每毫克和约59.1 ng *小时/毫升/毫克(每毫克对乙酰氨基酚)。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号